Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 3/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.34 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.31 |
| ▸ | LIPC | P11150 | 1/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.31 |
| ▸ | EED | O75530 | 1/20 | 0.31 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.31 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.31 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.31 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | CDK7 | P50613 | 1/20 | 0.31 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.31 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25257828 | 1.00 | KIT (0.39) | KITTLR7TLR8JAK1TNK2 | |
| SCHEMBL31270874 | 0.90 | KIT (0.36) | KITJAK1GPR119 | |
| SCHEMBL25819223 | 0.90 | KIT (0.36) | KITJAK1GPR119 | |
| SCHEMBL31270679 | 0.90 | KIT (0.37) | KITTLR7JAK1TNK2GRM1 | |
| SCHEMBL25301919 | 0.90 | KIT (0.37) | KITTLR7JAK1TNK2GRM1 | |
| SCHEMBL31270806 | 0.89 | GPR119 (0.34) | KITTLR7TLR8TBK1GPR119 | |
| SCHEMBL25256681 | 0.89 | GPR119 (0.34) | KITTLR7TLR8TBK1GPR119 | |
| SCHEMBL25294635 | 0.88 | TLR7 (0.41) | TLR7TLR8 | |
| SCHEMBL31270695 | 0.87 | KIT (0.38) | KITTLR7GPR119 | |
| SCHEMBL25296097 | 0.87 | TLR7 (0.40) | TLR7TLR8EEDRBBP4SUZ12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055119-A9 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD (CN) | 2026-02-26 | — | — | US | disclosed |
| US-20250257071-A9 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-08-14 | — | — | US | disclosed |
| US-20250195683-A1 | ANTIBODY-DRUG CONJUGATE, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEROF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-06-19 | — | — | US | disclosed |
| EP-4516321-A1 | ANTIBODY-DRUG CONJUGATE, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2025-03-05 | — | — | EP | disclosed |
| US-20250002502-A1 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD (CN) | 2025-01-02 | — | — | US | disclosed |
| EP-4458830-A1 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2024-11-06 | — | — | EP | disclosed |
| CN-118829451-A | Antibody drug conjugate, pharmaceutical composition and application thereof | 四川科伦博泰生物医药股份有限公司 | 2024-10-22 | — | — | CN | disclosed |
| WO-2023207710-A9 | ANTIBODY-DRUG CONJUGATE, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2024-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195683-A1 | ANTIBODY-DRUG CONJUGATE, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEROF | CD47, ABCB1, EGFR | KIT 457/4885TLR7 2638/4885TLR8 2007/4885 |
| US-20250257071-A9 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | CYP11B2, CYP11B1, CYP3A5 | KIT 1622/4885TLR7 2484/4885TLR8 3224/4885 |
| US-20260055119-A9 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | CYP11B1, CYP11B2, CYP2D6 | KIT 3679/4885TLR7 2700/4885TLR8 3592/4885 |
| US-20250002502-A1 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | CYP11B2, CYP11B1, CYP3A5 | KIT 1622/4885TLR7 2484/4885TLR8 3224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.